United Family Medicine Board Names Chief Executive Officer

ST. PAUL, Minn.–(BUSINESS WIRE)–United Family Medicine (UFM), a federally-qualified health center (FQHC) in St. Paul dedicated to meeting the health care demands of its community while contributing to the vitality of the region, announced today that its board of directors promoted Ann Nyakundi to CEO effective immediately.

Nyakundi joined the organization as interim CEO in October 2019, establishing priorities to re-design UFM’s care model to improve patients’ access to its services, maintain highest level health outcomes, and achieve compliance with the Health Resources Services Administration (HRSA), its federal regulator and primary funder. The resulting transformative changes, including migrating from its Allina-leased provider arrangement to hiring its own full complement of physicians, place UFM on track to attain regulatory compliance, while improving patients’ ability to see their doctors and health care team more quickly than ever before.

“It’s my desire and our collective responsibility to provide the best health care possible to every one of our patients, at the time that they need it, and we’re making numerous changes to meet this commitment,” said Nyakundi. “I’m grateful to UFM’s board of directors for the confidence it’s placed in me as its CEO, and excited to continue our work to place patients at the center of our response to community needs.”

Through the onset and continuing stressors of the Covid-19 pandemic, Nyakundi empowered her teams to improve access to care, such as the advanced practitioners who launched telemedicine as a service. This prompt response resulted in UFM regaining most of the patient visits that were delayed due to the pandemic, while significantly reducing UFM’s operating deficit and reliance on a part-time physician workforce. These cost efficiencies will allow UFM to expand dental and other services.

“Ann’s skill as a health care leader and her ethical and motivational orientation has steered United Family Medicine forward through the extreme challenges that its operating structure posed and the Covid-19 pandemic continues to present,” said Daymond Dean, UFM Executive Committee Board Member. “Our patients’ lives and well-being depend on their ability to receive the services that a community health center provides, and Ann is immeasurably qualified to ensure that UFM delivers those services and high-quality health care to our community.

Nyakundi pursued undergraduate and graduate medical anthropology and health care administration at the University of Michigan and University of Minnesota respectively, and brings to her role expertise in community health, philanthropy, strategic planning and health policy. Having experienced homelessness as a child without access to adequate options for high quality health care, inspired her career and commitment to public health. Most recently she volunteered for the Agency for Healthcare Research and Quality (AHRQ) as a National Expert for the New Models of Primary Care Workforce and Financing Project, provided strategic support to the National Marrow Donor Program and worked within the Primary Care Services Division of the American Cancer Society.

About United Family Medicine

United Family Medicine, a federally qualified health center in St. Paul, Minnesota, provides high quality primary care, dental services and

Read more

Precision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology’s Board of Directors | News

LEBANON, N.H., Nov. 24, 2020 /PRNewswire/ — Javelin Oncology, Inc. announced today that the company has named Dennis H. Langer, M.D., J.D. to the company’s board of directors as an independent director. Dr. Langer has served as a director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies. Dr. Langer was a Senior Vice President at GlaxoSmithKline plc, served as CEO of Neose Technologies, Inc., and was President of Dr. Reddy’s North American business. He is currently a director of Myriad Genetics, Inc., and was previously a director of Dicerna Pharmaceuticals, Inc. and Sirna Therapeutics, Inc.. Dr. Langer is a graduate of Columbia University, and earned an M.D. at Georgetown University School of Medicine and a J.D. at Harvard Law School.

“We are very fortunate to have Dennis’ counsel and unique skill set to help our team and board as we evolve our promising science towards creating cures for solid tumor cancer patients,” said Steven Yecies, Javelin’s Chief Executive Officer. “His track record and experience in moving promising science to ground-breaking therapies that help patients is a great match for Javelin’s needs. Dennis is a great example of the talent that we seek to surround ourselves with at Javelin and we look forward to his contributions. “

“Javelin has innovative and very promising immune-oncology technology and has assembled strong leadership in its management and on the board,” stated Dr. Langer. “I look forward to working with the company to advance the technology and make a difference for patients with solid cancers.”

More information about Dennis Langer is available at www.javelinoncology.com.

About Javelin Oncology

Javelin Oncology is a leader in precision immune medicine. The company has novel targeting and stratification capabilities that it is utilizing for its own proprietary efforts as well to create a services business to accelerate the science and use of precision immune medicine for others.

Learn more about Javelin Oncology at www.javelinoncology.com.

Contact info
Steven Yecies
CEO, Javelin Oncology
[email protected]

Source Article

Read more

United Family Medicine Board Names Chief Executive Officer – Press Release

ST. PAUL, Minn.–(Business Wire)–United Family Medicine (UFM), a federally-qualified health center (FQHC) in St. Paul dedicated to meeting the health care demands of its community while contributing to the vitality of the region, announced today that its board of directors promoted Ann Nyakundi to CEO effective immediately.

Nyakundi joined the organization as interim CEO in October 2019, establishing priorities to re-design UFM’s care model to improve patients’ access to its services, maintain highest level health outcomes, and achieve compliance with the Health Resources Services Administration (HRSA), its federal regulator and primary funder. The resulting transformative changes, including migrating from its Allina-leased provider arrangement to hiring its own full complement of physicians, place UFM on track to attain regulatory compliance, while improving patients’ ability to see their doctors and health care team more quickly than ever before.

“It’s my desire and our collective responsibility to provide the best health care possible to every one of our patients, at the time that they need it, and we’re making numerous changes to meet this commitment,” said Nyakundi. “I’m grateful to UFM’s board of directors for the confidence it’s placed in me as its CEO, and excited to continue our work to place patients at the center of our response to community needs.”

Through the onset and continuing stressors of the Covid-19 pandemic, Nyakundi empowered her teams to improve access to care, such as the advanced practitioners who launched telemedicine as a service. This prompt response resulted in UFM regaining most of the patient visits that were delayed due to the pandemic, while significantly reducing UFM’s operating deficit and reliance on a part-time physician workforce. These cost efficiencies will allow UFM to expand dental and other services.

“Ann’s skill as a health care leader and her ethical and motivational orientation has steered United Family Medicine forward through the extreme challenges that its operating structure posed and the Covid-19 pandemic continues to present,” said Daymond Dean, UFM Executive Committee Board Member. “Our patients’ lives and well-being depend on their ability to receive the services that a community health center provides, and Ann is immeasurably qualified to ensure that UFM delivers those services and high-quality health care to our community.

Nyakundi pursued undergraduate and graduate medical anthropology and health care administration at the University of Michigan and University of Minnesota respectively, and brings to her role expertise in community health, philanthropy, strategic planning and health policy. Having experienced homelessness as a child without access to adequate options for high quality health care, inspired her career and commitment to public health. Most recently she volunteered for the Agency for Healthcare Research and Quality (AHRQ) as a National Expert for the New Models of Primary Care Workforce and Financing Project, provided strategic support to the National Marrow Donor Program and worked within the Primary Care Services Division of the American Cancer Society.

About United Family Medicine

United Family Medicine, a federally qualified health center in St. Paul, Minnesota, provides high quality primary care, dental services and behavioral health

Read more

Precision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology’s Board of Directors

LEBANON, N.H., Nov. 24, 2020 /PRNewswire/ — Javelin Oncology, Inc. announced today that the company has named Dennis H. Langer, M.D., J.D. to the company’s board of directors as an independent director. Dr. Langer has served as a director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies. Dr. Langer was a Senior Vice President at GlaxoSmithKline plc, served as CEO of Neose Technologies, Inc., and was President of Dr. Reddy’s North American business. He is currently a director of Myriad Genetics, Inc., and was previously a director of Dicerna Pharmaceuticals, Inc. and Sirna Therapeutics, Inc.. Dr. Langer is a graduate of Columbia University, and earned an M.D. at Georgetown University School of Medicine and a J.D. at Harvard Law School.

“We are very fortunate to have Dennis’ counsel and unique skill set to help our team and board as we evolve our promising science towards creating cures for solid tumor cancer patients,” said Steven Yecies, Javelin’s Chief Executive Officer. “His track record and experience in moving promising science to ground-breaking therapies that help patients is a great match for Javelin’s needs. Dennis is a great example of the talent that we seek to surround ourselves with at Javelin and we look forward to his contributions. “

“Javelin has innovative and very promising immune-oncology technology and has assembled strong leadership in its management and on the board,” stated Dr. Langer. “I look forward to working with the company to advance the technology and make a difference for patients with solid cancers.”

More information about Dennis Langer is available at www.javelinoncology.com.

About Javelin Oncology

Javelin Oncology is a leader in precision immune medicine. The company has novel targeting and stratification capabilities that it is utilizing for its own proprietary efforts as well to create a services business to accelerate the science and use of precision immune medicine for others.

Learn more about Javelin Oncology at www.javelinoncology.com.

Contact info
Steven Yecies
CEO, Javelin Oncology
[email protected]

SOURCE Javelin Oncology

Related Links

https://javelinoncology.com/

Source Article

Read more

Mogrify Appoints Profs. Christine Mummery, Graziella Pellegrini and Giulio Cossu to Scientific Advisory Board

Leaders in stem cell research and cell therapy to help drive development of scalable off-the-shelf therapies for diseases with a high unmet clinical need

Mogrify Limited (Mogrify®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, has expanded its Scientific Advisory Board (SAB) with the appointment of three new members. Profs. Christine Mummery, Graziella Pellegrini and Giulio Cossu will apply their experience in the transition of stem cell approaches from proof-of-concept through the clinic to product approval, to support the Company in developing scalable off-the-shelf therapies for diseases with a high unmet clinical need.

Profs. Mummery, Pellegrini and Cossu join Mogrify’s SAB, comprising academic and industrial leaders in drug discovery, immunology, oncology, bioinformatics, cell reprogramming and regenerative medicine: Dr. Jane Osbourn, OBE, Dr. Lorenz Mayr, Prof. Julian Gough, Prof. Owen Rackham and Prof. Jose Polo.

Christine Mummery, PhD is a Professor of Developmental Biology in the Department of Anatomy and Embryology at Leiden University Medical Center and founded the first induced pluripotent stem cell core facility in the Netherlands. Prof. Mummery became a guest professor at the Technical University of Twente to develop organ-on-chip models based on stem cells, is Founding Chair of the European Organ-on-Chip Society and heads a multimillion-euro research program focused on implementing these models in human stem cell research. She is a member of the Royal Netherlands Academy of Science, past board member of the Netherlands Medical Research Council and holds European Research Council Grants to study cardiac development and disease in humans based on stem cell models. She is a former Editor-in-Chief of the International Society of Stem Cell Research (ISSCR) journal, Stem Cell Reports, and became President of the society in 2020.

Graziella Pellegrini, PhD is a Professor at the University of Modena and Reggio Emilia, Cell Therapy Program Coordinator at the Centre for Regenerative Medicine “Stefano Ferrari”, and Co-founder and R&D Director at Holostem Terapie Avanzate S.r.l. Prof. Pellegrini is renowned for her work in translational medicine and has developed epithelial stem cell-mediated cell and gene therapies for the treatment of severe eye and skin disease, including Holoclar®, the first stem cell-based medicinal product to be approved by the European Commission. Prof. Pellegrini is a recipient of the ISSCR and Louis-Jeantet Prize, and the Tissue Engineering and Regenerative Medicine International Society and European Tech Women Award, and has published over 100 peer-reviewed papers, book chapters and nine patents. She is also a founding member of the International Ocular Surface Society and is involved with numerous other societies, committees and meetings covering stem cells and regenerative medicine.

Giulio Cossu, MD is a Professor of Regenerative Medicine at The University of Manchester and visiting professor at the Max Delbruck Centre, Charitè in Berlin. He is a fellow of the Medical Academy, Accademia dei Lincei, and European Academy of Science. He has been Panel Chair at the European Research Council and a member of the Committee

Read more

Yale Medicine Board elects new female chair, four new members

Jessie Cheung, Contributing Photographer

The Yale Medicine Board has elected a new female chair and has nominated and ratified four other female faculty members.

Nita Ahuja, the current chair of the surgery department at the Yale School of Medicine and an assistant director at the Yale Cancer Center, was elected as the new chair of the board in October. The four other women appointed to the board were Michele Johnson, Marie Robert, Marietta Vazquez and Merceditas Villanueva. The appointment of these five new members increased the gender and racial equity of the 27-member board.

“A board governing practice should have racial and gender composition matching the members of the clinical practice they represent,” Margaret Bia — professor emerita of medicine and a member of the Committee on the Status of Women in Medicine, or SWIM — wrote in an email News. SWIM aims to address issues related to gender equality at the Yale School of Medicine.

According to Bia, the Yale Medicine Board, which represents Yale Medicine, has had a problem with diversity in the past. She mentioned that Paula Kavathas — professor of laboratory medicine, immunobiology and molecular, cellular and developmental biology — noticed this issue a few years ago while she was serving on the board and resolved to fix it.

As stated by Kavathas, the board is composed of 18 clinical chiefs, which were almost exclusively men, and nine ad hoc chairs. When she was a member of the board, only three of the clinical chiefs and one of the ad hoc chairs were female.

“At the time, the Yale Medicine group was about 40 percent female,” Kavathas said. “But when I looked at the [board] structure, they were more than 90 percent male.”

In an effort to change the board’s composition, Kavathas emailed all the women faculty in the clinical departments to ask them if they would like to serve on the board as an ad hoc member. She then recommended the candidates to Paul Taheri, the chief executive officer of Yale Medicine, and Roberta Hines, the head of the nominating committee for the board. The following year, nearly 40 percent of the board was female.

According to Gary Desir, previous chair of the Yale Medicine Board, this year, the board has taken new initiative to increase its diversity by focusing on additional outreach.

“The idea was to reach out more broadly than before and include SWIM, which is the Committee on the Status of Women in Medicine, and MORE, which is the Minority Organization for Retention and Expansion,” Desir said.

As per the initiative, the Yale Medicine Board reached out to the head of SWIM, Nina Stachenfeld, and asked her to suggest two candidates to be considered for the board, according to Bia. This led to the changes and additions to board leadership — the four new faculty members and new board chair. 

Ahuja, the board’s new chair, has served as the first female chair of surgery at Yale since February 2018, as well as

Read more

Idaho county health board overturns mask mandate despite hospitals hitting capacity

An Idaho county health board on Thursday voted to overturn a mandatory mask mandate just one day after the area’s main hospital reported that it was at 99 percent capacity amid the coronavirus pandemic. 

The board struck down the mandate in a 4-3 decision Thursday, with the county now recommending residents wear masks without imposing fines for noncompliance. 

According to the Spokesman-Review, the mandate was first implemented in Kootenai County in July following a spike in COVID-19 cases. However, the outlet reported that the mandate was largely ignored and not properly enforced by local authorities. 

Health board member Glen Bailey had proposed ending the mandate, arguing that it “restricts people’s right of choice and ability to comply or not comply under penalty of law,” according to the Spokesman-Review. 

The decision came after officials from area hospital Kootenai Health on Wednesday issued a press release saying that it was almost at capacity, adding that nearby hospitals were also almost full and would not accept new patients. 

The press release added that based on tests at Kootenai Health, the county is “seeing the highest rate of positivity since the start of the pandemic,” and that it was “looking at hospitals beyond our normal transfer area to see what is available” to accommodate additional patients. 

“Our hospitals, health district and emergency responders are relying on our community for support,” the statement read. “The best way forward is to keep up with efforts that will flatten the uptick in cases in our region.” 

The press release then outlined several actions it recommended for people to help stem the spread of COVID-19 in the area, including wearing face masks around people outside of one’s household, washing hands for at least 20 seconds, avoiding public areas and cleaning frequently touched surfaces often. 

Amid public backlash on the health board’s decision, the Panhandle Health District issued a public statement alerting people that its coronavirus hotline “is mainly staffed with volunteers that have nothing to do with the Board’s decisions.”

“They manage their fair share of angry callers with grace and patience, but please direct comments about the board meeting to the board,” the notice said.

Idaho has been one of several states experiencing spikes in COVID-19 cases in recent weeks, with the Idaho Department of Health and Welfare reporting 950 newly confirmed cases on Thursday, bringing the state’s confirmed case total to 56,600. 

Kootenai County is now in the Panhandle Health District’s highest risk coronavirus category. According to The New York York Times COVID-19 database, the county had 96 newly confirmed coronavirus cases on Thursday, bringing the total to 3,724 infections and 48 deaths.

Source Article

Read more

Conroe ISD board highlights dyslexia’s impact on learning

For hundreds of students and parents in the Conroe Independent School District, dyslexia and other reading and learning disabilities have had a significant impact on their education. As part of Dyslexia Awareness Month, the CISD Board of Trustees included a special recognition of dyslexia at its Tuesday meeting.

A group of parents with students with reading disorders has been in conversation with the district for a while now about how dyslexia services are conducted, which programs are being used, what they want the district to put more resources into, and the funding that the district dyslexia services receive.

“The Texas Education Agency and the American Institutes of Research identify dyslexia as “the most commonly diagnosed learning disability” affecting the education of children. Students experiencing dyslexia may also struggle with related disorders such as dysgraphia, dyscalculia, developmental auditory imperceptions, dysphasia, specific developmental dyslexia, developmental dysgraphia, and developmental spelling disability,” according to the special recognition that the board included. “The most recent data available from the Texas Education Agency indicates that only 3.5% to 4.0% of Texas students are identified as dyslexic. Peer-reviewed research indicates that up to 20% of the student population may suffer from the difficulties associated with dyslexia.”

Board member Scott Moore, who recommended the recognition, read a special proclamation to be included in the official meeting minutes.

Nicole May is a district parent with two sons, both diagnosed with dyslexia, and a member of the parent group. She has addressed the board several times to talk about dyslexia services and what the parent group thinks the district could be doing better. At Tuesday’s meeting, she brought her younger son to say hello to the board, and thank them for the special recognition. But she also took the opportunity to continue her advocacy.


“My goal tonight is to continue keeping dyslexic students in our district a focus and to continue addressing the need for more for our population,” May said. “The questions I ponder often are ‘Do the decision-makers in our district see the need for more for our population? And do you see the potential of our population in society?’”

While looking over STAAR data for the district from the 2019-20 May said she found the dyslexia population identified in some of the scores for writing and reading tests that did not meet the state average. She questioned why the district started a new dyslexia program last year, asking directly if it was because there were students in the district that were no thriving under the old program.

“My insight, it was not the previous program that failed these students,” May said. “Rather, it was the lack of commitment to execute the program to the level required to gain success.”

In her previous addresses to the board, May encouraged the district to use the maximum time allowable for dyslexia services instead of the minimum and to keep dyslexia services classes to the smallest number of students each to allow for more personal instruction.

May was not the only

Read more

The New York Academy Of Medicine Welcomes New Board Chair Dr. Wayne Riley, President Of SUNY …

New York, NY, Oct. 21, 2020 (GLOBE NEWSWIRE) — The New York Academy of Medicine (NYAM) and SUNY Downstate Health Sciences University jointly announced Wayne J. Riley, MD, MPH, MBA, MACP, as Chair of NYAM’s Board of Trustees. Dr. Riley is the 17th president of the Brooklyn-based SUNY Downstate Health Sciences University, where he also holds tenured professorships in internal medicine, health policy, and management. Dr. Riley joined the NYAM Board of Trustees in 2017.  

He is the first African American to lead the organization’s board as he succeeds James Flynn, MS, President, Deerfield Management Company LP.

With nearly 175 years of leadership in medical science, advocacy to improve medicine, public health, and disparities in healthcare, NYAM’s mission to attain health equity in pursuit of a healthier New York—and the world—has never been more vital. The COVID-19 pandemic has laid bare the inequities—furthered by a 400-year legacy of systemic racism—that have created poor health outcomes for millions, many in communities of color. NYAM is responding to this public health crisis with the passion and unique know-how of its longstanding institutional expertise, as well as a commitment to addressing social justice issues to reach health equity. 

Since joining the NYAM board, Dr. Riley’s guidance and leadership have significantly impacted NYAM’s strategic plans, including its new  Action Agenda for Health Equity. Fueled by the current state of health inequities, Dr. Riley’s ongoing contributions and leadership of the Board of NYAM and its partnership with the executive leadership will help lay the groundwork to improve the health and well-being of New Yorkers in the years to come. 

“Dr. Riley’s leadership of the NYAM’s Board of Trustees will enhance and enrich NYAM’s perspectives in our pursuit of disrupting common thinking patterns, changing systems and bolstering the influence of our work to result in meaningful change,” said NYAM President Dr. Judith A. Salerno, MD, MS. “We are fortunate to benefit from his wealth of experience as a top physician, educator, and administrator, and I can think of no one better to head our Board as we continue to pursue our vision of a world where everyone has the opportunity to live a healthy life.”

“I am honored to assume the role of Chairman of the Board of The New York Academy of Medicine,” said Dr. Riley. “At this critical time in New York and our nation, while we deal with a global pandemic, unjustifiable and worrisome distrust of medicine and science, social justice matters, systemic racism, and persistent health disparities—all of which significantly impact communities of color—understanding the intersectionality of where these variables meet begs for viable solutions, and systematic, positive outcomes. NYAM’s voice, advocacy, and leadership remain critically important in affecting positive change, and I look forward to the work we will continue to engage in as a Board and an organization.”

 “We are pleased to congratulate Dr. Riley on his historic appointment as Chairman of NYAM’s Board of Trustees,” said Dr. Steven J. Corwin, president, and CEO of NewYork-Presbyterian. “Dr. Riley is

Read more

The Alliance for Regenerative Medicine Announces Election of 2021 Officers, Executive Committee, and Board of Directors

Washington, DC, Oct. 21, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, announced today the election of its 2021 Officers, Executive Committee, and Board of Directors.

The Executive Committee and Board of Directors oversee the formation and execution of ARM’s strategic priorities and focus areas over the coming year. The committee and board are subject to an annual re-election or rotation process, with nominations and approval by the ARM membership and current Board.

“We are pleased to welcome such an accomplished group of executives to the 2021 ARM board of directors,” said Janet Lambert, CEO of ARM. “As scientists, commercial leaders, and regulatory experts, the new members of the board will be instrumental in helping ARM and its members deliver transformative and potentially curative regenerative medicines to patients around the world.” 

ARM 2021 Officers:

Emile Nuwaysir, Ph.D. – President and CEO, BlueRock Therapeutics (Chairman)

Usman ‘Oz’ Azam, M.D. – President and CEO, Tmunity Therapeutics (Vice Chairman)

Amy Butler, Ph.D. – President, Biosciences, Thermo Fisher Scientific (Secretary)

Devyn Smith, Ph.D. – COO, Sigilon Therapeutics (Treasurer)

ARM 2021 Executive Committee:
*new to the Executive Committee for 2021

Usman ‘Oz’ Azam, M.D. – President and CEO, Tmunity Therapeutics

Amy Butler, Ph.D. – President, Biosciences, Thermo Fisher Scientific 

* Miguel Forte, M.D., Ph.D. – CEO, Bone Therapeutics

Claudia Mitchell, MBA, Ph.D. – SVP, Product and Portfolio Strategy, Astellas Pharma

Emile Nuwaysir, Ph.D. – President and CEO, BlueRock Therapeutics 

Bob Smith, MBA – SVP, Global Gene Therapy Business, Pfizer Inc.

Devyn Smith, Ph.D. – COO, Sigilon Therapeutics

* Arthur Tzianabos, Ph.D. – President and CEO, Homology Medicines

* Christopher Vann – COO, Autolus Therapeutics 

ARM 2021 Board of Directors:
*new to the Board for 2021

Usman ‘Oz’ Azam, M.D. – President and CEO, Tmunity Therapeutics

Ronald Bartek – Co-Founder and President, Friedreich’s Ataxia Research Alliance

Amy Butler, Ph.D. – President, Biosciences, Thermo Fisher Scientific

Bradley Campbell, MBA – President and COO, Amicus Therapeutics

Cindy Collins, MBA – President and CEO, Editas Medicine

* Maria Fardis, Ph.D., MBA – President and CEO, Iovance Biotherapeutics

Miguel Forte, M.D., Ph.D. – CEO, Bone Therapeutics

Jonathan Garen, M.S. – CBO, uniQure

* Bobby Gaspar, M.D., Ph.D. – CEO, Orchard Therapeutics

Michael Hunt, ACA – CFO, ReNeuron

Jerry Keybl, Ph.D. – Senior Director, Cell & Gene Therapy, MilliporeSigma

* Louise Rodino-Klapac, Ph.D. – SVP, Gene Therapy, Sarepta Therapeutics

Ann Lee, Ph.D. – SVP and Head of Cell Therapy Development & Operations, Bristol Myers Squibb

* Dave Lennon, Ph.D. – President, Novartis Gene Therapies

Bruce Levine, Ph.D. – Barbara and Edward Netter Professor in Cancer Gene Therapy, and Founding Director, Clinical Cell and Vaccine Production Facility, Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania

John Maslowski, M.S. – President and CEO, Castle Creek Pharmaceuticals

Claudia Mitchell, MBA, Ph.D. – SVP, Product and Portfolio Strategy, Astellas Pharma

* Adora Ndu, PharmD,

Read more
  • Partner links